Overview

Safety, Tolerability and Pharmacokinetics of LNK01004 Ointment in Adults With Atopic Dermatitis.

Status:
COMPLETED
Trial end date:
2024-06-18
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the Safety, Tolerability, and Pharmacokinetics of LNK01004 ointment (0.3%, 1.0%, and 1.5%) vs vehicle twice daily (BID) in Adults Patients with Atopic Dermatitis.
Phase:
PHASE1
Details
Lead Sponsor:
Lynk Pharmaceuticals Co., Ltd